Corporate Patient
PDMS Log In nSight Log In

Outcomes

Life-Changing Outcomes

The RNS System delivers unmatched seizure control that
lets your patients take back their lives.

Effectiveness

Unmatched Seizure Control1-3

Rapid and long-term seizure reduction was demonstrated in the largest FDA-reviewed prospective study in neuromodulation history for focal drug-resistant epilepsy (DRE).

View Publication

3 Year Median Seizure Reduction (%)

 
DBS
MORE Registry3 (n=101)
 
VNS
Study Group E01-E052 (n=93)
 
RNS® System
Post Approval Study1 (n=255)
 

Quality of Life

Restart your patients' lives

Patients reported significant improvements in all domains of quality of life after just 1 year.5

  • Improved cognition

    Cognitive function improved significantly. (P=0.01)

    Patients experienced meaningful gains across key cognitive areas:

    • Attention

      Improved focus and clarity

    • Concentration

      Better ability to stay on task

    • Language

      Enhanced verbal communcation

    • Memory

      Clearer recall and retention

  • Better emotional health.

    Mental health elevated significantly. (P=0.01)

    Quality of life improved across emotional and social dimensions:

    • Emotional well-being

      Greater sense of balance

    • Energy Level

      More vitality throughout the day

    • Social support

      Stronger connections with others

  • Less worry. More living.

    Epilepsy concern reduced significantly. (P=0.01)

    Patients reported decreased anxiety around their condition:

    • Seizure worry

      Reduced fear and uncertainty

    • Medication effects

      Fewer concerns about treatment

    • Health discouragement

      Greater optimism about the future

  • Better physical health.

    Physical health improved significantly. (P=0.01)

    Daily life became easier with measurable physical gains:

    • Pain

      Reduced discomfort

    • Physical function

      Better mobility and movement

    • Role limitations

      Fewer restrictions on daily activities

Safety

The RNS System is a safe, non-destructive epilepsy therapy with no chronic stimulation side effects.**7,8

  • Side Effects Seen with DBS 8,9

  • Depression

  • Anxiety

  • Memory Impairment

  • Sleep Disruption

  • Side Effects Seen with VNS 10

  • Voice Alternations

  • Throat Pain and Cough

  • Shortness of Breath

  • Difficulty Swallowing

“If you were having one seizure every week, now you’re having one seizure per month. That’s a lot better control and a lot more certainty in how you day’s going to be.”

Dr. John Rolston
Director of Epilepsy Surgery, Brigham and Women’s Hospital

  • Long term median seizure reduction of 82% at 3 years. 1

  • Rapid seizure reduction of 63% at 6 months. 1

  • 43% of patients were seizure free for 6+ months. *1

  • 3x lower rate of SUDEP vs ASM Placebo 4

Easily get your patients started with The RNS® System

Whether you're evaluating your first candidate or you want to establish the RNS System as your standard of care, we are here to help.

Contact NeuroPace Find a Center

Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important prescribing and safety information at www.NeuroPace.com/safety. Refer to the labeling for a description of the RNS System and its components, indications for use, contraindications, warnings, cautions, adverse events and instructions for use.

Note: Therapies were studied using different study designs. Caution must be exercised when comparing results.

  1. Eliashiv, D. et al. Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy, Three-year Efficacy and Interim Safety Results. Neurology 2026;106:e214875
  2. Morris et al, Neurology, 1999.
  3. Kaufmann et al., Epilepsia, 2024
  4. Compared to placebo arm of ASM trial. 2.3/1000 rate of SUDEP in RNS System prospective studies (AAN Oral Presentation, April 2025) vs 6.9/1000 rate of SUDEP in Anti-seizure Medication (ASM) placebo; Ryvlin et al, Lancet Neurol, 2011
  5. Meador KJ et al., Epilepsy Behav., 2015
  6. GEE. Loring DW et al., Epilepsia, 2015
  7. Nair, et al., Neurology, 2020
  8. Sprengers et al., Cochrane Database of Systematic Reviews, 2017.
  9. Voges et al., Epilepsia, 2015; n=9, N values are small and caution must be taken while interpreting results.
  10. VNS Therapy® System Epilepsy Physician’s Manual, Mar 2026.

* At some point during the study.

**At therapeutic settings

© 2026 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are registered trademarks of NeuroPace, Inc., Mountain View, CA

NP 260047 Rev1 / Rev Date 2026-04